The bill sHB6830 File No. 365 aims to create a Prescription Drug Affordability Advisory Council within the Health Care Cabinet of the Office of Health Strategy, effective from October 1, 2023. The council's mandate is to provide recommendations on policy initiatives and review health care cost trends, including pharmaceutical pricing and hospital costs. It will be composed of 15 members appointed by various state leaders, representing a wide range of stakeholders such as the American Association of Retired Persons, health insurance industry, labor unions, pharmacists, and more. Members will serve four-year terms, up to a maximum of two terms, and will meet at least quarterly. They will not receive compensation but will be reimbursed for expenses. The council is also required to submit an annual report starting January 1, 2025. The fiscal impact of establishing the council is estimated to be $145,000 in FY 24 and $148,000 in FY 25, which includes hiring a Planning Analyst to support the council's administrative activities. The bill analysis details the council's membership, duties, and reporting requirements. The bill has been favorably passed by the Insurance and Real Estate Committee. There are no specific insertions or deletions mentioned in the provided text regarding changes to current law.